Overview of Dr. Zhang
Dr. Jun Zhang is an oncologist in Houston, TX and is affiliated with multiple hospitals in the area, including Houston Methodist Hospital, Houston Methodist Sugar Land Hospital, Houston Methodist Willowbrook Hospital, Houston Methodist Baytown Hospital, Houston Methodist West Hospital, Houston Methodist The Woodlands Hospital, and Houston Methodist Clear Lake Hospital. She received her medical degree from Hunan Medical University and has been in practice 29 years. She is one of 91 doctors at Houston Methodist Hospital and one of 38 doctors at Houston Methodist Clear Lake Hospital who specialize in Oncology. She has more than 10 publications and over 50 citings.
Education & Training
Vidant Medical Center/East Carolina UniversityFellowship, Hematology and Medical Oncology, 2009 - 2012
Novant Health New Hanover Regional Medical CenterResidency, Internal Medicine, 2007 - 2008
Hunan Medical UniversityClass of 1992
Certifications & Licensure
TX State Medical License 2012 - 2027
NC State Medical License 2007 - 2014
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors Start of enrollment: 2020 Dec 14
Roles: Contact
- Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer with Progression on First-Line Immunotherapy with or Without Chemotherapy Start of enrollment: 2021 Oct 14
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Chemotherapy, immunotherapy, or combination first-line treatment for metastatic urothelial carcinoma of the bladder: A large real-world experience.Sanjana Ranganathan, Carlos Riveros, Jiaqiong Xu, Siqi Hu, Michael Geng
Urologic Oncology. 2024-09-01 - 2 citations5-Hydroxymethylcytosine in Cell-Free DNA Predicts Immunotherapy Response in Lung Cancer.Jianming Shao, Yitian Xu, Randall J Olsen, Saro Kasparian, Kai Sun
Cells. 2024-04-19 - 8 citationsA Phase 2 Study of In Situ Oncolytic Virus Therapy and Stereotactic Body Radiation Therapy Followed by Pembrolizumab in Metastatic Non-Small Cell Lung Cancer.Jian Guan, Kai Sun, Carlo A Guerrero, Junjun Zheng, Yitian Xu
International Journal of Radiation Oncology, Biology, Physics. 2024-04-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
